Eladynos Európska únia - slovenčina - EMA (European Medicines Agency)

eladynos

theramex ireland limited - abaloparatide - osteoporosis, postmenopausal; osteoporosis - homeostáza vápnika - liečba osteoporózy u postmenopauzálnych žien so zvýšeným rizikom zlomeniny.

Softine 0,03 mg/3 mg filmom obalené tablety Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

softine 0,03 mg/3 mg filmom obalené tablety

theramex ireland limited, Írsko - drospirenón a etinylestradiol - 17 - anticoncipientia

Softinelle 0,02 mg/3 mg filmom obalené tablety Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

softinelle 0,02 mg/3 mg filmom obalené tablety

theramex ireland limited, Írsko - drospirenón a etinylestradiol - 17 - anticoncipientia

Seasonique 0,15 mg/0,03 mg + 0,01 mg filmom obalené tablety Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

seasonique 0,15 mg/0,03 mg + 0,01 mg filmom obalené tablety

theramex ireland limited, Írsko - levonorgestrel a etinylestradiol - 17 - anticoncipientia

Yselty Európska únia - slovenčina - EMA (European Medicines Agency)

yselty

theramex ireland limited - linzagolix choline - leiomyóm - hypofýzové a hypotalamické hormóny a analógy - yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.

Zoely Európska únia - slovenčina - EMA (European Medicines Agency)

zoely

theramex ireland limited - nomegestrol acetát, estradiol - antikoncepcie - pohlavné hormóny a modulátory z genitálny systém, - oral contraception,.

Intrarosa Európska únia - slovenčina - EMA (European Medicines Agency)

intrarosa

endoceutics s.a. - prasterone - postmenopause - iné pohlavné hormóny a modulátory z genitálneho systému - intrarosa je indikovaná na liečbu vulválnej a vaginálnej atrofie u postmenopauzálnych žien so stredne ťažkými až ťažkými symptómami.

Kimmtrak Európska únia - slovenčina - EMA (European Medicines Agency)

kimmtrak

immunocore ireland limited - tebentafusp - uveal neoplasms - antineoplastické činidlá - kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (hla)-a*02:01-positive adult patients with unresectable or metastatic uveal melanoma.

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Európska únia - slovenčina - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrel hydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotické činidlá - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Krystexxa Európska únia - slovenčina - EMA (European Medicines Agency)

krystexxa

crealta pharmaceuticals ireland limited - pegloticase - dna - antiguty prípravky - liek krystexxa je indikovaný na liečbu ťažkou slabnúcej chronickej uzlovitou dospelých pacientov, ktorí majú aj erozívna spoločné zapojenie a ktorí zlyhali k normalizácii sérovej kyseliny močovej s inhibítory xantínoxidázy max.12 medicínsky primerané dávky alebo pre ktorých sú tieto lieky kontraindikované.